Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs

This article was originally published in The Pink Sheet Daily

Executive Summary

In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.

You may also be interested in...

Reimbursement Briefs: Medicaid Savings, Kcentra Payment, Formulary Discrimination Concerns

Cost reductions in Medicaid associated with increased drug use; Medicare add-on payments for Kcentra extended; patient groups seek formulary non-discrimination provisions in HHS rule.

The Sovaldi Anniversary? Burgess Wants Part D Milestone To Change How Gov’t Values Rx Spending

Congressional budget projections should use longer time horizons, Vice-Chair of House Energy and Commerce Health Subcommittee argues; meanwhile former FDA Commissioner suggests costly drugs could be paid for on a mortgage model.

Medication Therapy Management To Expand In Part D Under CMS Rule

CMS expects the proposed changes to medication therapy management will make 55% of Medicare beneficiaries eligible for MTM services, which CMS says has been shown to improve drug therapy outcomes and reduce health care costs.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts